How much funding has Amber Therapeutics raised?

Amber Therapeutics has raised $100.0M in total funding, most recently a Series A round.

Who are Amber Therapeutics's investors?

Amber Therapeutics's investors include New Enterprise Associates, Oxford Science Enterprises, F-Prime Capital, Lightstone Ventures, Intuitive Ventures.

Where is Amber Therapeutics headquartered?

Amber Therapeutics is headquartered in London, United Kingdom.

What industry is Amber Therapeutics in?

Amber Therapeutics operates in Healthcare, Medical Devices, Hardware.

How many employees does Amber Therapeutics have?

Amber Therapeutics has 11-50 employees.

Amber Therapeutics

Q: When was Amber Therapeutics founded?

Amber Therapeutics was founded in 2021.

Doing the extraordinary to restore the ordinary

London, United Kingdom · Founded 2021 · $100.0M raised

Healthcare

Medical Devices

Hardware

Headquarters: London
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: ambertherapeutics.com
Total Funding: $100.0M
Last Round: $100.0M Series AJun 2024
Rounds: 2

About

Amber Therapeutics was founded in 2021 by Aidan Crawley, Tim Denison, Stefan De Wachter, and Charles Knowles with a mission to develop breakthrough neuromodulation therapies for areas of unmet clinical need. Its lead program, Amber-UI, is the world's first fully implantable, closed-loop adaptive neuromodulation therapy targeting the pudendal nerve to treat mixed urinary incontinence — a condition affecting 40 million women in the US. The company completed successful first-in-human implants in the AURA-2 feasibility study and is advancing toward US FDA approval.

Summary

Amber Therapeutics is a Healthcare company based in London, United Kingdom, founded in 2021. It has raised $100.0M in total across 2 rounds, most recently a $100.0M Series A round in Jun 2024. Investors include New Enterprise Associates, Oxford Science Enterprises and F-Prime Capital.